Please login to the form below
Ionis
This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.
Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
Biogen and Ionis have revealed topline data from an early-stage study evaluating its investigational Alzheimer’s disease drug candidate BIIB080 (IONIS-MAPT Rx). ... Alzheimer's disease," said C Frank Bennett, chief scientific officer and franchise
Latest news
-
GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2
GlaxoSmithKline has announced positive results from a phase 2a study of its Ionis-partnered antisense medicine for chronic hepatitis B virus (CHB) infection. ... As part of the licensing deal, Ionis is set to receive fees and milestone payments of up to
-
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy
In the ATTR polyneuropathy indication it has competition from Alnylam’s injectable drugs Onpattro (patisiran) and Ionis’ Tegsedi (inotersen), which were approved for that use in Europe in 2018.
-
Merck strengthens KRAS stake with Taiho and Astex partnership
Other competitors in the KRAS inhibitor race include Mirati, Boehringer Ingelheim, Johnson &Johnson/Wellspring and AstraZeneca/Ionis.
-
Biogen bets on Ionis’ early-stage Alzheimer’s drug
payout. . The drug – IONIS-MAPTRx – is an antisense therapy designed to reduce production of microtubule-associated protein tau (MAPT) or tau in the central nervous system. ... In pre-clinical research, IONIS-MAPTRx demonstrated prevention of
-
Pfizer pays $250m upfront to Akcea for phase 2 antisense drug
Has potential in cardiovascular and metabolic diseases. Pfizer has bolted on an antisense drug with potential in cardiovascular and metabolic diseases to its pipeline via a licensing deal with Ionis’ Akcea ... Founded in 2015, Akcea spun out of Ionis
GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2
Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy
Merck strengthens KRAS stake with Taiho and Astex partnership
Biogen bets on Ionis’ early-stage Alzheimer’s drug
Pfizer pays $250m upfront to Akcea for phase 2 antisense drug
More from news
Approximately 17 fully matching, plus 33 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Standing in its way is a similarly priced antisense rival from Ionis and Akcea – Tegsedi (inotersen) – as well as Pfizer’s fast- growing Vyndaqel/Vyndamax (tafamidis), which is approved for hATTR
-
Where next in Alzheimer’s disease R&D?
The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in
-
Deal Watch October 2018
Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
While Onpattro has outshone Ionis’ product in safety and efficacy, analysts see Onpattro’s lack of cardiovascular claims in its US label as a weak point. ... England’s NICE is just beginning its review of Onpattro (in tandem with a review of
-
The European Medicines Agency: PRIME’d for access?
Since March 2018 Roche, with Ionis, have added another PRIME drug to their portfolio. ... RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease.
20 for 2020 – Five pharma leaders to watch in 2020
Where next in Alzheimer’s disease R&D?
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
The European Medicines Agency: PRIME’d for access?
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
- Cuttsy+Cuttsy awarded Gold accreditation by Investors in People
- Nudging someone in the right direction isn’t always easy – that’s where behavioural science comes in
- OPEN Health Acquires ARK
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Lucid Group celebrates a double win at Communiqué 2021
- Live Webinar: Driving Healthcare Decisions with Natural Language Processing
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
